What happened

Two studies published in JAMA have found an association between a blood biomarker and advanced chronic traumatic encephalopathy, or CTE. The findings offer a lead for research into diagnosis during life. They do not establish a validated diagnostic test that doctors can now use to confirm CTE in patients.S2R1R2R3

The Boston University and Banner Health study examined blood collected during life from 21 former American football players whose brains were later examined after death. Eighteen had CTE: sixteen with advanced disease and two with earlier-stage disease. The other three did not have CTE on examination.S2S3R1

Blood levels of the marker were higher in the advanced-CTE group. Five participants also had Alzheimer’s disease-related changes, and their levels were highest. The distinction matters because an increased reading was not confined to people with CTE alone, while low-stage CTE did not show the same elevation.S2S3R1

Why it matters

CTE currently requires examination of brain tissue after death for confirmation. Symptoms can overlap with those of other brain diseases, making assessment during life difficult. The candidate marker concerns tau, a protein that normally supports nerve cells but forms abnormal tangles in Alzheimer’s disease.S2R3

The separate Washington University research examined the tau fragment eMTBR-tau243 in a broader study of 229 participants. Its CTE blood analysis involved eleven people. Its cerebrospinal-fluid analysis also found elevated levels in Alzheimer’s disease and some inherited forms of frontotemporal degeneration, reinforcing the need to test how specifically the marker identifies CTE.S2R2

The background

The Boston study’s authors describe important limits to their sample. It consisted of male former football players recruited through a specialist research centre who subsequently donated their brains. The authors say this restricts how widely the findings can be applied, particularly to women and to other sources of repeated head impacts.R1

The small number with early-stage disease is another limitation. It restricted the researchers’ ability to determine whether the marker distinguishes early CTE from no CTE. The Washington University team likewise did not reliably identify early-stage disease in the samples described in the news reports.S2R1

What happens next

Larger studies must establish diagnostic accuracy and the ability to distinguish CTE from other conditions. In an accompanying editorial, Carla Palleis and Günter Höglinger describe possible future uses in selecting research participants and evaluating interventions, conditional on validation. Those applications remain research goals, not demonstrated benefits for patients.R1R3

Michael Alosco, a study author, said the work remained in the discovery phase. He described accurate detection and opportunities for treatment trials as prospects that depended on future studies validating the findings.S3